DFX Intelligence
Private Credit Intelligence
The capital structure graph behind private markets. Who lent, to whom, under which sponsor, through which facility, how large the piece was, when it matures and what changed, with a filing behind every number. A BDC piece is that BDC's piece, a sum of pieces is a lower bound, and a sponsor is named with the evidence that names it.
Borrowers
171 borrower groups currently held
A borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.
| Borrower | Sponsor | BDCs | Principal held | On cost | Next maturity | First seen |
|---|---|---|---|---|---|---|
| Bamboo US BidCo LLC Pharmaceuticals | unattributed | 21 | at least $903M | 101c | Oct 1, 2029 | Dec 31, 2021 |
| Karo Kairos Intermediateco AB Pharmaceuticals | unattributed | 1 | at least $764M | 99c | Aug 26, 2032 | Sep 30, 2025 |
| Kona Buyer, LLC Healthcare & Pharmaceuticals | unattributed | 17 | at least $624M | 100c | Jun 27, 2027 | Dec 31, 2021 |
| Puma Buyer, LLC Pharmaceuticals | unattributed | 9 | at least $381M | 101c | Mar 1, 2032 | Dec 31, 2022 |
| Covetrus, Inc Pharmaceuticals | Clayton, Dubilier & Rice, LLC carried | 13 | at least $338M | 101c | Oct 1, 2029 | Sep 30, 2022 |
| DBG Consolidated Holdings Pty Ltd (dba Arrotex Pharmaceuticals) | unattributed | 1 | at least $318M | 105c | Oct 29, 2032 | Sep 30, 2025 |
| Allied Benefit Systems Intermediate LLC Healthcare & Pharmaceuticals | unattributed | 13 | at least $297M | 100c | Oct 1, 2030 | Dec 31, 2022 |
| Apple AU Finco Pty Ltd Pharmaceuticals | unattributed | 3 | at least $258M | 97c | May 27, 2033 | Mar 31, 2026 |
| Catalent Creek Parent, Inc Pharmaceuticals | unattributed | 1 | at least $200M | 100c | Dec 18, 2031 | Dec 31, 2024 |
| NH Kronos Buyer, Inc Pharmaceuticals | unattributed | 7 | at least $198M | 100c | Jan 1, 2033 | Dec 31, 2022 |
| Solvias AG Pharmaceuticals | unattributed | 2 | at least $149M | 112c | Feb 27, 2030 | Mar 31, 2025 |
| Biogaran Bastille Bidco SAS Pharmaceuticals | unattributed | 1 | at least $143M | 96c | Oct 7, 2032 | Mar 31, 2026 |
| Pharmalogic Holdings Corp Pharmaceuticals | unattributed | 3 | at least $138M | 99c | Jun 21, 2030 | Jun 30, 2024 |
| Aspen Apple SG Bidco Pte. Ltd Pharmaceuticals | unattributed | 1 | at least $124M | 98c | Mar 19, 2033 | Jun 30, 2026 |
| Poseidon Midco AB Pharmaceuticals | CNK Equity Partners I, LLC carried | 2 | at least $110M | 102c | Sep 17, 2031 | Sep 30, 2023 |
| AEG Vision Healthcare & Pharmaceuticals | Riata Capital Group, LLC carried | 2 | at least $100M | 100c | Mar 27, 2027 | Jun 30, 2024 |
| PAI Financing Merger Sub LLC Pharmaceuticals | unattributed | 2 | at least $98.0M | 100c | Feb 13, 2032 | Sep 30, 2024 |
| Zelis Cost Management Buyer, Inc Healthcare & Pharmaceuticals | unattributed | 9 | at least $86.4M | 98c | Sep 1, 2029 | Dec 31, 2022 |
| Soliant Lower Intermediate, LLC Healthcare & Pharmaceuticals | unattributed | 9 | at least $83.7M | 74c | Jul 1, 2031 | Dec 31, 2023 |
| Ardelyx, Inc Pharmaceuticals | unattributed | 4 | at least $80.5M | 101c | Jul 31, 2030 | Dec 31, 2022 |
| Industria Chimica Emiliana Srl Pharmaceuticals, Biotechnology & Life Sciences | unattributed | 1 | at least $75.5M | 93c | Sep 1, 2028 | Dec 31, 2021 |
| Ellkay, LLC Healthcare & Pharmaceuticals | unattributed | 7 | at least $71.3M | 97c | Sep 14, 2030 | Dec 31, 2021 |
| Bridges Consumer Healthcare Intermediate LLC Pharmaceuticals | Charlesbank Capital Partners, LLC carried | 5 | at least $70.4M | 100c | Dec 22, 2031 | Dec 31, 2023 |
| 1261229 BC LTD Pharmaceuticals | unattributed | 2 | at least $68.2M | 100c | Oct 8, 2030 | Mar 31, 2025 |
| Alcresta Buyer, Inc Pharmaceuticals | unattributed | 4 | at least $67.4M | 101c | Mar 12, 2031 | Dec 31, 2023 |
| Druid City Infusion, LLC Pharmaceuticals | unattributed | 2 | at least $65.2M | 189c | Oct 4, 2029 | Sep 30, 2024 |
| Bamboo Health Holdings, LLC Healthcare & Pharmaceuticals | unattributed | 6 | at least $64.8M | 100c | May 1, 2028 | Mar 31, 2024 |
| Paradigm Parent, LLC Healthcare & Pharmaceuticals | Impresa Management LLC carried | 6 | at least $61.9M | 95c | Apr 16, 2032 | Dec 31, 2021 |
| BCTO Bobsled Purchaser, Inc Healthcare & Pharmaceuticals | unattributed | 4 | at least $61.6M | 100c | Jan 16, 2033 | Dec 31, 2025 |
| SCP Eye Care HoldCo, LLC Healthcare & Pharmaceuticals | unattributed | 10 | at least $59.8M | 100c | Oct 5, 2029 | Dec 31, 2022 |
| Mamba Purchaser, Inc Healthcare & Pharmaceuticals | Charlesbank Capital Partners, LLC inferred | 7 | at least $59.5M | 100c | Oct 1, 2031 | Dec 31, 2021 |
| Resistance Holdings, Inc Pharmaceuticals | unattributed | 4 | at least $59.1M | 100c | Mar 1, 2031 | Sep 30, 2022 |
| Emerge Intermediate, Inc Pharmaceuticals | unattributed | 4 | at least $57.6M | 99c | Aug 31, 2027 | Sep 30, 2021 |
| Specialty Pharma III, Inc Healthcare & Pharmaceuticals | unattributed | 10 | at least $57.3M | 100c | Dec 23, 2032 | Feb 29, 2024 |
| Celerion Buyer, Inc Healthcare & Pharmaceuticals | Court Square Capital carried | 13 | at least $52.5M | 100c | May 8, 2033 | Dec 31, 2022 |
| Alcresta Therapeutics Inc Pharmaceuticals | Linden Capital Partners carried | 4 | at least $50.4M | 100c | Mar 1, 2031 | Mar 31, 2024 |
| Smile Brands, Inc Healthcare and Pharmaceuticals | Freeman Spogli & Co. carried | 7 | at least $47.3M | 83c | Oct 12, 2027 | Dec 31, 2021 |
| CRH Healthcare Purchaser, Inc Healthcare & Pharmaceuticals | Freeman Spogli & Co. carried | 6 | at least $45.7M | 106c | Sep 17, 2031 | Sep 30, 2021 |
| Waystar Technologies, Inc Healthcare & Pharmaceuticals | unattributed | 11 | at least $45.6M | 100c | Oct 1, 2029 | Dec 31, 2021 |
| Genmab GENMAB A Pharmaceuticals | unattributed | 1 | at least $43.9M | 101c | Dec 10, 2032 | Dec 31, 2025 |
| Avid Bioservices Space Finco, Inc Pharmaceuticals | unattributed | 2 | at least $42.6M | 100c | Feb 5, 2031 | Mar 31, 2025 |
| LS Clinical Services Holdings, Inc Pharmaceuticals | unattributed | 3 | at least $40.9M | 71c | Jun 18, 2029 | Mar 31, 2022 |
| Opal Bidco SAS Pharmaceuticals | unattributed | 5 | at least $38.8M | 100c | Apr 1, 2032 | Mar 31, 2025 |
| Apollo Intelligence Healthcare & Pharmaceuticals | unattributed | 2 | at least $37.9M | 99c | Jun 1, 2028 | Sep 30, 2022 |
| TerSera Therapeutics LLC Pharmaceuticals | unattributed | 8 | at least $37.6M | 100c | Apr 4, 2030 | Dec 31, 2021 |
| Arcutis Biotherapeutics, Inc Pharmaceuticals | unattributed | 3 | at least $36.6M | 105c | Aug 31, 2029 | Dec 31, 2022 |
| Bianalisi S.p.A Healthcare & Pharmaceuticals | unattributed | 2 | at least $34.7M | 106c | Feb 26, 2032 | Mar 31, 2025 |
| Nidda Healthcare Holding AG Pharmaceuticals, Biotechnology & Life Sciences | unattributed | 1 | at least $33.0M | 99c | Feb 1, 2030 | Sep 30, 2025 |
| LSCS Holdings, Inc Pharmaceuticals | unattributed | 20 | at least $32.3M | 99c | Feb 23, 2032 | Dec 31, 2021 |
| Hoosier Intermediate, LLC Healthcare & Pharmaceuticals | unattributed | 3 | at least $31.6M | 101c | Nov 15, 2028 | Dec 31, 2021 |
Page 1 of 4Next
Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.